Jeil Pharmaceutical Applies for Approval of 'Beoba Tablets' for Overactive Bladder Treatment

[Asia Economy Reporter Lee Gwan-joo] Jeil Pharmaceutical announced on the 25th that it has completed the new drug application for the overactive bladder treatment drug ‘Beoba Tablets’.

Beoba Tablets (active ingredient Vibegron) is a new drug for overactive bladder developed by Japan’s Kyorin Pharmaceutical. Jeil Pharmaceutical has completed a bridging Phase 3 clinical trial to obtain domestic approval.

Previously, Jeil Pharmaceutical conducted a Phase 1 clinical trial last year for the purpose of direct production. If Beoba Tablets receive final approval from the Ministry of Food and Drug Safety, the company plans to supply the drug domestically through in-house production.

Beoba Tablets selectively act on the bladder’s beta-3 (β-3) adrenergic receptors, relaxing the detrusor muscle of the bladder, helping to treat symptoms such as frequent urination, urgency, and urge urinary incontinence. According to the company, it is more effective in treating overactive bladder compared to existing drugs and has fewer side effects, improving symptoms and quality of life for patients with overactive bladder.

A Jeil Pharmaceutical official stated, “Having confirmed promising therapeutic efficacy through the bridging clinical trial, we plan to quickly commercialize the drug and enter the bladder treatment market,” adding, “We also plan to expand indications in the future, including improving overactive bladder symptoms in male patients with benign prostatic hyperplasia.”

This content was produced with the assistance of AI translation services.